Robert J Morgan Jr
Overview
Explore the profile of Robert J Morgan Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
551
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morgan Jr R, Armstrong D, Alvarez R, Bakkum-Gamez J, Behbakht K, Chen L, et al.
J Natl Compr Canc Netw
. 2016 Sep;
14(9):1134-63.
PMID: 27587625
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for...
2.
Kurzrock R, Colevas A, Olszanski A, Akerley W, Arteaga C, Carson 3rd W, et al.
J Natl Compr Canc Netw
. 2015 Nov;
13(11):1337-46.
PMID: 26553764
Background: With advances such as next-generation sequencing (NGS) increasing understanding of the basis of cancer and its response to treatment, NCCN believes it is important to understand how molecular profiling/diagnostic...
3.
4.
Kummar S, Oza A, Fleming G, Sullivan D, Gandara D, Naughton M, et al.
Clin Cancer Res
. 2015 Jan;
21(7):1574-82.
PMID: 25589624
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of...
5.
6.
Morgan Jr R, Alvarez R, Armstrong D, Burger R, Chen L, Copeland L, et al.
J Natl Compr Canc Netw
. 2013 Oct;
11(10):1199-209.
PMID: 24142821
These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and...
7.
Morgan Jr R, Alvarez R, Armstrong D, Burger R, Castells M, Chen L, et al.
J Natl Compr Canc Netw
. 2012 Nov;
10(11):1339-49.
PMID: 23138163
These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new...
8.
Chao J, Synold T, Morgan Jr R, Kunos C, Longmate J, Lenz H, et al.
Cancer Chemother Pharmacol
. 2011 Nov;
69(3):835-43.
PMID: 22105720
Background: 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with...
9.
Morgan Jr R, Alvarez R, Armstrong D, Boston B, Burger R, Chen L, et al.
J Natl Compr Canc Netw
. 2011 Jan;
9(1):82-113.
PMID: 21233246
No abstract available.
10.